Literature DB >> 16912476

Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: way to endeavor.

Poyin Huang1, Chun-Hung Chen, Yuan-Han Yang, Ruey-Tay Lin, Feng-Cheng Lin, Ching-Kuan Liu.   

Abstract

BACKGROUND: The eligibility for recombinant tissue plasminogen activator (rtPA) is rare. We analyze the reasons for exclusion from rtPA among patients who were admitted to our hospital within 3 h.
METHODS: A strict protocol for hyperacute stroke was set in a university teaching hospital. Consecutive patients activating the protocol from June 2004 to October 2005 were prospectively registered and entered into a computerized database. The patients were excluded from rtPA according to the modified exclusion criteria from the National Institute of Neurological Disorders and Stroke rtPA trial.
RESULTS: Of the 182 patients activating the protocol, only 11 (6.04%) received intravenous rtPA and 4 (2.2%) IA thrombolysis. Patients were excluded for multiple reasons, and the main reasons for exclusion were minor or improving stroke (46.15%), hypertension (35.16%), insufficient time to complete studies or onset beyond 3 h after reconfirmation (24.17%) and intracranial hemorrhage (15.93%). Of 167 excluded patients, 72 (43.11%) were excluded by a single criterion, 53 (31.73%) by 2 criteria and 29 (17.36%) by 3 criteria. The mean time from hospital arrival to presentation to a neurologist was 9.24 +/- 15.11 min (n = 164, median = 8.00, mode = 10, range = 0-65). The mean time from hospital arrival to computed tomography (CT) was 21.67 +/- 23.95 min (n = 167, median = 20.00, mode = 10, range = 4-68).
CONCLUSION: An intrahospital stroke code was implemented to minimize intrahospital delay. However, only 11 patients received intravenous rtPA and 4 IA thrombolysis at our hospital from June 2004 to October 2005. The result brings into question the neurologist's conservative interpretation of the criteria and the necessity to clearly define some criteria. Furthermore an intrahospital stroke code should also be implemented for inpatients to maximize the eligibility for rtPA. Copyright (c) 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16912476     DOI: 10.1159/000094994

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  9 in total

Review 1.  Executive (dys)function after stroke: special considerations for behavioral pharmacology.

Authors:  Jessica M Povroznik; Jenny E Ozga; Cole Vonder Haar; Elizabeth B Engler-Chiurazzi
Journal:  Behav Pharmacol       Date:  2018-10       Impact factor: 2.293

Review 2.  Inflammatory cytokines in experimental and human stroke.

Authors:  Kate Lykke Lambertsen; Knut Biber; Bente Finsen
Journal:  J Cereb Blood Flow Metab       Date:  2012-06-27       Impact factor: 6.200

3.  Rapid brain penetration of interleukin-1 receptor antagonist in rat cerebral ischaemia: pharmacokinetics, distribution, protection.

Authors:  A D Greenhalgh; J Galea; A Dénes; P J Tyrrell; Nancy J Rothwell
Journal:  Br J Pharmacol       Date:  2010-05       Impact factor: 8.739

4.  Unsuspected coagulopathy rarely prevents IV thrombolysis in acute ischemic stroke.

Authors:  N S Rost; S Masrur; M A Pervez; A Viswanathan; L H Schwamm
Journal:  Neurology       Date:  2009-11-25       Impact factor: 9.910

5.  Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study.

Authors:  James Galea; Kayode Ogungbenro; Sharon Hulme; Andrew Greenhalgh; Leon Aarons; Sylvia Scarth; Peter Hutchinson; Samantha Grainger; Andrew King; Stephen J Hopkins; Nancy Rothwell; Pippa Tyrrell
Journal:  J Cereb Blood Flow Metab       Date:  2010-07-14       Impact factor: 6.200

6.  Barriers of thrombolysis therapy in developing countries.

Authors:  Kavian Ghandehari
Journal:  Stroke Res Treat       Date:  2011-03-17

7.  Leukocyte TNFR1 and TNFR2 Expression Contributes to the Peripheral Immune Response in Cases with Ischemic Stroke.

Authors:  Rikke B Hansen; Cathrine C H Laursen; Niala Nawaz; Jonna S Madsen; Helle H Nielsen; Christina Kruuse; Arne Møller; Matilda Degn; Kate L Lambertsen
Journal:  Cells       Date:  2021-04-09       Impact factor: 6.600

8.  Are in-Hospital Delays Important Obstacles in Thrombolytic Therapy Following Acute Ischemic Stroke?

Authors:  Jay Chol Choi; Sa-Yoon Kang; Ji-Hoon Kang; Yeo-Ju Ko; Jong-Myon Bae
Journal:  J Clin Neurol       Date:  2007-06-20       Impact factor: 3.077

9.  Challenges and Opportunities for Emergency Department Sepsis Screening at Triage.

Authors:  Michael R Filbin; Jill E Thorsen; James Lynch; Trent D Gillingham; Corey L Pasakarnis; Roberta Capp; Nathan I Shapiro; Theodore Mooncai; Peter C Hou; Thomas Heldt; Andrew T Reisner
Journal:  Sci Rep       Date:  2018-07-23       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.